Do you want to read an article? Please log in or register.
Antifibrotic therapy and progressive lung fibrosis
Interstitial Lung DiseasePulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir Rev.
Collins BF, Raghu G
doi: 10.1183/16000617.0022-2019.
Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children
PLoS Pathog.
Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC
doi: 10.1371/
RECOMMENDED
Interstitial Lung Disease
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A, RELIEF investigators.
doi: 10.1016/S2213-2600(20)30554-3
Pulmonary Fibrosis
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Lancet Respir Med.
Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group
doi: 10.1016/
Lung Cancer
Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial
Int J Radiat Oncol Biol Phys.
Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S
doi: 10.1016/j.ijrobp.2018.04.015.
RECOMMENDED
Pulmonary Fibrosis
Targeting Proteases in Cystic Fibrosis Lung Disease: Paradigms, Progress, and Potential
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
McKelvey MC, Weldon S, McAuley DF, Mall MA, Taggart CC
doi: 10.1164/rccm.201906-1190PP.
RECOMMENDED
Pulmonary Fibrosis
Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
Stanojevic S, Davis SD, Perrem L, Shaw M, Retsch-Bogart G, Davis M, Jensen R, Clem CC, Isaac SM, Guido J, Jara S, France L, McDonald N, Solomon M, Sweezey N, Grasemann H, Waters V, Sanders DB, Ratjen FA
doi: 10.1183/13993003.03380-2020
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
Eur Respir J.
Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M
doi: 10.1183/13993003.02279-2019.
RECOMMENDED
EmphysemaInterstitial Lung DiseasePulmonary Fibrosis
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS® study)
Eur Respir J.
Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V
doi: 10.1183/13993003.02718-2020.